Acta Diabetologica

, Volume 51, Issue 1, pp 151–153 | Cite as

A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance

  • Francesco ZaccardiEmail author
  • Dario Pitocco
  • Francesca Martini
  • Salvatore Caputo
  • Luca Miele
  • Antonio Grieco
  • Giovanni Ghirlanda
Case Report


We describe a case report of a patient who developed transient type 2 diabetes after a drug-induced (esomeprazole) sub-acute hepatitis. This case evidences the pathophysiological relevance, also in humans, of liver inflammation in the pathogenesis of type 2 diabetes.


Steatohepatitis Insulin resistance Type 2 diabetes Drug-induced hepatitis 


Conflict of interest

The authors declare no conflict of interest relevant to this paper.


  1. 1.
    Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219–246 (Review)PubMedCrossRefGoogle Scholar
  2. 2.
    Virtue S, Vidal-Puig A (2010) Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. Biochim Biophys Acta 1801(3):338–349PubMedCrossRefGoogle Scholar
  3. 3.
    Solinas G, Karin M (2010) JNK1 and IKK{beta}: molecular links between obesity and metabolic dysfunction. FASEB J 24(8):2596–2611PubMedCrossRefGoogle Scholar
  4. 4.
    Fabbrini E, Magkos F, Mohammed BS et al (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106(36):15430–15435PubMedCrossRefGoogle Scholar
  5. 5.
    Lanthier N, Molendi-Coste O, Horsmans Y et al (2010) Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 298(1):G107–G116PubMedCrossRefGoogle Scholar
  6. 6.
    Huang W, Metlakunta A, Dedousis N et al (2010) Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59(2):347–357PubMedCrossRefGoogle Scholar
  7. 7.
    Romero-Gómez M, Otero MA, Suárez-García E et al (1999) Acute hepatitis related to omeprazole. Am J Gastroenterol 94(4):1119–1120PubMedCrossRefGoogle Scholar
  8. 8.
    Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344(7):495–500 (Review)PubMedCrossRefGoogle Scholar
  9. 9.
    Bernal W, Auzinger G, Dhawan A et al (2010) Acute liver failure. Lancet 376:190–201PubMedCrossRefGoogle Scholar
  10. 10.
    Crouch MA, Mefford IN, Wade EU (2012) Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med 25(1):50–54PubMedCrossRefGoogle Scholar
  11. 11.
    Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M et al (2011) Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2(12):217–220PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Hove KD, Færch K, Bödvarsdóttir TB et al (2010) Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients—a retrospective analysis. Diabetes Res Clin Pract 90(3):e72–e74PubMedCrossRefGoogle Scholar
  13. 13.
    Mefford IN, Wade EU (2009) Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 73(1):29–32PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Francesco Zaccardi
    • 1
    Email author
  • Dario Pitocco
    • 1
  • Francesca Martini
    • 1
  • Salvatore Caputo
    • 1
  • Luca Miele
    • 2
  • Antonio Grieco
    • 2
  • Giovanni Ghirlanda
    • 1
  1. 1.Diabetes Care UnitCatholic UniversityRomeItaly
  2. 2.Internal Medicine InstituteCatholic UniversityRomeItaly

Personalised recommendations